WeVote
Log In

Bill

Bill

HB 1169

classify medetomidine as a Schedule III controlled substance and establish permissible uses.

2026 Regular Session Introduced by Bobbi Andera and 9 co-sponsors

South Dakota reclassifies medetomidine as Schedule III controlled substance while permitting established medical and veterinary uses.

Signed by the Governor on 2026-03-09 H.J. 534
#controlledsubstances #publichealthandsafety
0
WeVote Research Nonpartisan
Bill Summary · HB 1169

Legislative bill overview

HB 1169 reclassifies medetomidine, a sedative and analgesic drug, from an unscheduled substance to Schedule III controlled substance status in South Dakota. The bill simultaneously establishes permissible uses for the substance, likely for veterinary and medical applications where it currently has legitimate purposes.

Why is this important

Medetomidine is widely used in veterinary medicine as a sedative for animals and in human medical settings in some contexts. Classifying it as Schedule III brings regulatory oversight while the permissible uses provision ensures legitimate medical and veterinary practitioners can continue accessing it without legal barriers. This reflects balancing drug safety concerns with medical necessity.

Potential points of contention

  • Definition of permissible uses: The bill's effectiveness depends on how narrowly or broadly "permissible uses" are defined; vague language could create enforcement ambiguity or unintended restrictions on legitimate veterinary care
  • Schedule III classification rationale: Some may question whether Schedule III (moderate abuse potential) is appropriate versus other schedules, or whether scheduling was necessary given existing FDA/DEA oversight of veterinary drugs
  • Access implications for rural veterinarians: Additional regulatory requirements for Schedule III substances could increase compliance burdens and costs for veterinary practices, potentially affecting rural animal care availability

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.